Summit Cancer Care

Savannah, Georgia 31405

3 studies enrolling now · 18 studies all time

What they study most

Advanced Breast Cancer, Advanced Solid Tumors, Breast Cancer, Chemotherapy-induced Nausea and Vomiting, Locally Recurrent or Metastatic Breast Cancer, Lung Cancer, Lymphoma, Non-Hodgkin, Melanoma, Metastatic Breast Cancer, Multiple Myeloma, Non Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Cancer

Studies at this site

• A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer — Recruiting now
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. — Recruiting now
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• Connect® MM- The Multiple Myeloma Disease Registry — Stopped early
• Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects — Running, not enrolling
• Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer — Completed
• Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC — Status unconfirmed
• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen — Completed
• Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study — Completed
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer — Completed
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer — Withdrawn before enrolling
• Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC — Completed
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma — Completed
• Expanded Access Program With Nivolumab to Treat Melanoma — NO_LONGER_AVAILABLE
• Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer — Completed
• Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone — Completed